Clene Inc. cash flow statement
In fiscal 2025, Clene Inc.'s operations generated −$18.5m of cash; it spent $39,000 on capital projects, leaving free cash flow of −$18.6m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −19 | −35 | −39 | −30 | −21 | −19 | −16 |
| Depreciation and amortisation | 1 | 1 | 1 | 2 | 2 | 1 | 1 |
| Stock-based pay | 1 | 12 | 9 | 9 | 8 | 6 | 5 |
| Capital spending | 0 | 1 | 5 | 0 | 0 | 0 | 0 |
| Free cash flow | −19 | −36 | −44 | −31 | −21 | −19 | −16 |
| Free cash flow after stock pay | −20 | −48 | −53 | −40 | −29 | −25 | −21 |
| Shares issued | — | 0 | 11 | — | — | — | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −3,023 | −4,865 | −5,011 | −4,744 | −3,992 | −4,799 | −4,528 | −2,588 |
| Depreciation and amortisation | 406 | 405 | 404 | 366 | 365 | 360 | 355 | 353 |
| Stock-based pay | 2,188 | 1,801 | 1,947 | 1,367 | 1,703 | 1,365 | 1,312 | 1,040 |
| Capital spending | 1 | 1 | 0 | 0 | 11 | 28 | — | 0 |
| Free cash flow | −3,024 | −4,866 | −5,011 | −4,744 | −4,003 | −4,827 | — | −2,588 |
| Free cash flow after stock pay | −5,212 | −6,667 | −6,958 | −6,111 | −5,706 | −6,192 | — | −3,628 |
| Shares issued | 2,036 | — | 2,673 | 2,304 | 3,266 | — | — | — |
Compare with peers
- Celldex Therapeutics, Inc. cash flow
- Cervomed Inc. cash flow
- Ibio, Inc. cash flow
- Lisata Therapeutics, Inc. cash flow
- AIM Immunotech Inc. cash flow
Head to head: CLDX vs CLNNCLNN vs CRVOCLNN vs IBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies